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Loss-of-Function Mutations in the PRPS1 Gene
Cause a Type of Nonsyndromic X-linked
Sensorineural Deafness, DFN2
Xuezhong Liu,1,2,11 Dongyi Han,2,11 Jianzhong Li,2 Bing Han,2 Xiaomei Ouyang,1 Jing Cheng,2
Xu Li,3,4 Zhanguo Jin,2 Youqin Wang,5 Maria Bitner-Glindzicz,6 Xiangyin Kong,7 Heng Xu,7
Albena Kantardzhieva,8 Roland D. Eavey,8 Christine E. Seidman,9,10 Jonathan G. Seidman,9,10
Li L. Du,1 Zheng-Yi Chen,8 Pu Dai,2 Maikun Teng,3,4 Denise Yan,1 and Huijun Yuan2,*
We report a large Chinese family with X-linked postlingual nonsyndromic hearing impairment in which the critical linkage interval
spans a genetic distance of 5.41 cM and a physical distance of 15.1 Mb that overlaps the DFN2 locus. Mutation screening of the
PRPS1 gene in this family and in the three previously reported DFN2 families identiﬁed four different missense mutations in PRPS1.
These mutations result in a loss of phosphoribosyl pyrophosphate (PRPP) synthetase 1 activity, as was shown in silico by structural
analysis and was shown in vitro by enzymatic activity assays in erythrocytes and ﬁbroblasts from patients. By in situ hybridization,
we demonstrate expression of Prps1 in murine vestibular and cochlea hair cells, with continuous expression in hair cells and postnatal
expression in the spiral ganglion. Being the second identiﬁed gene associated with X-linked nonsyndromic deafness, PRPS1 will be
a good candidate gene for genetic testing for X-linked nonsyndromic hearing loss.X-linked deafness is a clinically and genetically heteroge-
neous disorder that accounts for ~5% of all congenital
deafness1 and < 2% of nonsyndromic hearing loss
(NSHL).2 Despite its relative rarity as compared to domi-
nant and recessive forms of NSHL, the ﬁrst nuclear gene
implicated in hereditary NSHL was POU3F4 (MIM
300039), identiﬁed in 1995 as the cause of X-linked deaf-
ness at the DFN3 locus (MIM 304400).3 The DFN2 locus
(MIM 304500), which was mapped before the DFN3 locus,
is associated with NSHL that is phenotypically complex.
Several families mapping to this locus segregate postlin-
gual progressive NSHL,4–6 although a large, four-genera-
tion, British American pedigree segregating congenital
profound NSHL was the ﬁrst DFN2 family to be identiﬁed.
Obligate female carriers in this family have mild to
moderate NSHL that is more pronounced in the higher
frequencies.
Manolis and colleagues reported the second DFN2
family, an American family with ﬁve affected males and
two obligate female carriers. The affected males all showed
an upward-sloping audio proﬁle, with severe hearing
impairment in the low and middle frequencies and better
hearing in the high frequencies. The loss, which was post-
lingual and progressive, was initially noted between 7 and
20 years of age. The obligate female carriers in this family
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The Aidentiﬁed a large Chinese family with X-linked postlingual
NSHL that also mapped to the DFN2 locus.6
In this study, we present another large Chinese family
(GZ-Z052) segregating X-linked NSHL. This family spans
ﬁve generations and includes 106 members. Fourteen
persons with hearing loss and 29 normal-hearing persons
participated in this research, which was approved by the
ethics committee of the Chinese PLA General Hospital.
Seventeen family members (nine males and eight females)
had hearing impairment that ranged from mild to
profound in degree. Age at onset of hearing impairment
was between 5 and 15 years for males and in the ﬁfth
decade for females.
Affected males exhibited symmetric, progressive, severe
to profound hearing loss with ﬂat-shaped audio proﬁles
at 24–50 years of age (Figure 1A and Table 1). One affected
male (IV-21) also had a ten-day history of gentamicin
exposure (dosage unknown) for bronchitis at age 5 and
ﬁrst noted bilateral hearing impairment the following
year. However, from his audio proﬁle, which is identical
to that of the other affected males in the pedigree, it
appears that his hearing loss is unlikely to be secondary
to aminoglycoside exposure.
Obligate female carriers had either symmetric or asym-
metric hearing loss that varied from mild to moderate
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Figure 1. Chinese Family GZ-Z052 with X-linked Heriditary NSHL
(A) Audiograms of some affected male and female subjects (red, right ear; black, left ear). IV-21, who has a history of the use of
aminoglycosides, had exactly same audiogram pattern as that of IV-9 and IV-36, suggesting that his hearing impairment was not due
to aminoglycoside exposure. The hearing impairment of female carriers is progressive but not completely linked with increasing age.
(B) Haplotype analysis of the Chinese family GZ-Z052. The segregating haplotype associated with the NSHL is indicated by a black bar,
delimited by markers DXS8020 and DXS8055 on chromosome Xq22.hearing impairment was observed in individuals III-5, III-
11, III-17, III-25, and III-29 at ages ranging from 47 to 64
years, whereas bilateral severe to profound hearing loss
was documented in individual III-2 at age 71 (Figure 1A).
One female carrier, III-27, had completely normal hearing
at age 52.
Distortion products otoacoustic emissions (DPOAEs)
were measured in four affected males (IV-1, IV-9, IV-34,
and IV-36) and two female carriers (III-27 and III-29) and
were found to be signiﬁcantly below the noise ﬂoor bilater-
ally in the males and in the right ear of female carrier III-29
(data not shown). Female carrier III-27 showed a com-
pletely normal result of the DPOAEs test. Three out of six
affectedmales reported low-frequency tinnitus at the onset
of hearing loss (Table 1). Computed tomography of the
temporal bones in two affected males was normal, as was
comprehensive clinical testing including blood and urine
analysis, biochemical examination of blood (which specif-
ically excluded gout), B-ultrasonography of the urinary
system, and electrocardiography. No vestibular symptoms
were reported (Table 1).66 The American Journal of Human Genetics 86, 65–71, January 8, 20Linkage analysis, completed with the use of DNA from
23 persons, generated a two-point LOD score of 2.45 at
[q] ¼ 0 for marker DXS1106 on Xq22. Genotypic data for
11 additional markers ﬂanking DXS1106 resulted in a
maximum two-point LOD score of 4.25 at [q] ¼ 0 with
marker DXS8096 (Table S1, available online) and deﬁned
the boundaries of the disease interval as DXS8020 (prox-
imal, deﬁned by recombination events occurring in
III-11,III-15, III-17, and IV-21) and DXS8055 (distal,
deﬁned by a recombination event in IV-1 and IV-21),
a 5.4 -cM genetic interval that overlaps DFN2 (Figure 1B).
Of the 119 positional candidate genes in this interval,
we selected 14 genes for mutation screening—GLA
(MIM 300644), HNRPH2 (MIM 300610), NGFRAP1 (MIM
300361), TCEAL1 (MIM 300237), MORF4L2 (MIM
300409), ARMCX2 (MIM 300363), PLP1 (MIM 300401),
RNF128 (MIM 300439), PRPS1 (MIM 311850), MID2
(MIM 300204), COL4A5 (MIM 303630), NXT2 (MIM
300320), PAK3 (MIM 300142), and TIMM8A (MIM
300356)—on the basis of their inclusion in the Morton
Cochlear EST database.7 Sequence analysis of seven coding10
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Onset Left Ear Right Ear Plasmaa Urineb
IV-1 Male 50 10 No 106 106 No 231 3846 Normal Normal
IV-9 Male 36 14 No 88 96 No NT NT NT NT
IV-13 Male 30 8 No 69 71 Yes 289 4148 Normal Normal
IV-21 Male 31 6 Yes 89 84 Yes 399 2785 Normal Normal
IV-34 Male 28 5 No 82 87 No 322 3138 Normal Normal
IV-36 Male 24 8 No 85 78 Yes 380 4624 Normal Normal
III-2 Female 71 50 No 94 113 No 288 3187 Normal Normal
III-5 Female 56 53 No 57 33 Yes 156 3541 Normal Normal
III-11 Female 64 55 No 21 27 No 310 3166 Normal Normal
III-15 Female 57 50 No 41 60 Yes NT NT NT NT
III-17 Female 55 51 No 63 22 No 304 3535 Normal Normal
III-25 Female 53 40 No 31 61 No NT NT NT NT
III-29 Female 47 45 No 33 70 No 298 5078 Normal Normal
NT, not tested; PTA, pure tone average.
a The normal range is 90-420 mmol/L.
b The normal range is 2400-5900 mmol/L.exons of PRPS1 and about 100 base pairs (bp) of their ﬂank-
ing intronic sequences in two affected members (IV-1 and
IV-36) and one unaffected member (IV-7) identiﬁed a
G-to-A transition at position 193 in exon 2 (Figure 2C)
that results in an Asp65-to-Asn (D65N) substitution in
the a helix at the N terminus. Direct sequence analysis
demonstrated that this mutation cosegregated with the
deafness phenotype in 43 persons in the extended family.
In affected individuals from the family reported by Cui
et al.,6 we identiﬁed a T-to-C transition affecting the nucle-
otide position 869 in exon 7 of PRPS1 (Figure 2E) and
leading to an Ile290-to-Thr (I290T) substitution at the C
terminus. Both the D65 and I290 amino acids are highly
conserved from zebraﬁsh to human, and neither mutation
was seen in 1025 unrelated control chromosomes of
Chinese background (data not shown), supporting the
pathogenicity of both mutations.
In the British American DFN2 family reported by Tyson
and colleagues, we identiﬁed a G-to-A transition at nucleo-
tide position 259 (Figure 2D) that replaces a nonpolar small
hydrophobic amino acid—alanine—with an uncharged,
polar, larger amino acid— threonine (A87T), and in the
American DFN2 family reported by Manolis et al., we iden-
tiﬁed a G-to-A transition at nucleotide 916 that results in
a glycine-for-arginine exchange at codon 306 (G306R)
(Figure 2F). Both A87 and G306 are also evolutionarily
conserved across species from zebraﬁsh to human and
were absent in 1475 control Chinese chromosomes and
450 chromosomes of European descent.
PRPS1 encodes phospho-ribosylpyrophosphate synthe-
tase 1 (PRS-I; EC 2.7.6.1), which catalyzes the reaction ofThe Aribose-5-phosphate (R5P) with ATP to yield AMP and
PRPP (5-phosphoribosyl-1-pyrophosphate), which is nec-
essary for the de novo and salvage pathways of purine-,
pyrimidine-, and pyridine-nucleotide biosynthesis. The
open reading frame of human PRPS1 consists of 957 bp
coding for 318 amino acid residues.8 Eriksen et al. reported
the structure of B. subtilis phosphoribosyl pyrophosphate
synthetase and analyzed the structural basis of the catalytic
mechanism, revealing several regions and residues impor-
tant for binding of substrates (ATP and R5P) and effectors
(ADP, Pi, and Mg2þ).9 The enzyme requires phosphate
for activation and uses Mg2þ for activity, and it is subject
to purine-nucleotide (ADP and GDP) feedback inhibi-
tion.10 The crystal structure of human PRS-I reveals that
the active site comprises the binding sites for ATP and
R5P and consists of three primarily structural elements,
namely the ﬂexible loop (residues Phe92–Ser108), the PPi
(pyrophosphate)-binding loop (residues Asp171–Gly174),
and the ﬂag region (residues Val30–Ile44 of an adjacent
subunit), respectively.11 Any structural changes of the
above three elements would be likely to inﬂuence the cata-
lytic speciﬁcity and efﬁciency of PRS-I and alter its enzy-
matic activity. On the basis of the structural analysis of
the wild-type PRS-I in complex with AMP (PDB ID:
2HCR), we used PyMOL to predict the likely functional
impact of D65N, A87T, I290T, and G306R on PRS-I enzy-
matic activity. Residue Asp65 (on the a2 helix) interacts
with the residue Lys34 from loop3 (on the middle of the
ﬂag region) by hydrogen bonds and ﬁrms the conﬁgura-
tion of loop3. The replacement of the negatively charged
Asp with a polar and uncharged Asn (D65N) changes themerican Journal of Human Genetics 86, 65–71, January 8, 2010 67
Figure 2. Mapping Intervals and Mutation Analysis of the Four DFN2 Families
(A) Idiogram of the X chromosome with the described DFN2 loci. The linkage intervals and ﬂanking markers of four DFN2 families are
indicated in colored fonts and bars (red, Chinese family GZ-Z052; green, British American family; black, Chinese family reported by Cui
et al.;6 blue: American family).
(B) The genomic structure of PRPS1 depicting the positions of four DFN2 mutations.
(C–F) DNA sequence chromatograms showing four different missense mutations identiﬁed in affected males of four DFN2 families,
compared to wild-type controls.conﬁguration of the loop3 and impairs the ATP-binding
ability of the adjacent PRS-I subunit (Figure 3A). Ala87 is
located at the middle of the b5 strand (the second b strand
in an anti-parallel b sheet, also one of end points of ﬂexible
ATP-binding loop). The substitution of the hydrophobic
Ala with a polar and uncharged Thr (A87T) may alter the
secondary structure of the whole antiparallel beta sheet
and would thus depress the ATP-binding efﬁciency (Fig-
ure 3B). The PRS-I protein contains two primary domains
that are connected by two short, ﬂexible loops (Leu145-
Ala147, loop11; Ile290-Ser293, loop22). The I290T substi-
tution is located at the beginning of loop22. Replacement
of a hydrophobic Ile with a polar and uncharged Thr is pre-
dicted to change the conﬁguration of loop22, and it may
thus alter the enzymatic activity (Figure 3C). The Gly306
residue is located at the middle of loop23, very close to
the allosteric site of PRS-I. Replacement of the polar and
uncharged residue Gly with a positively charged, much
larger residue Arg (G306R) tends to inﬂuence the allosteric
regulatory mechanism of the enzyme (Figure 3D).
Expression analysis performed by quantitative real-time
PCR on total RNA isolated from leukocytes via the RNA
Blood Mini Kit (QIAGEN, Valencia, CA, USA) showed that68 The American Journal of Human Genetics 86, 65–71, January 8, 20the average expression level of PRPS1 in four affectedmales
(IV-1, IV-9, IV-34, and IV-36) of familyGZ-Z052was compa-
rable to the expression level in two female carriers (III-27
and III-29), two unaffected males (IV-5 and IV-7), and two
unrelated controls (Table S2). To assess the functional
consequence of the D65N mutation, we measured PRS-I
enzymatic activity in erythrocytes from four affectedmales
(IV-1, IV-9, IV-34, and IV-36), two carrier females (III-27 and
III-29), and two unaffected males (IV-5 and IV-7) of family
GZ-Z052, as well as two unrelated healthy controls (C-1
and C-2). (Standard deviations were calculated from three
experiments.) The assay is based on high-performance
liquid chromatography measurement of AMP, which is
produced in equimolar amounts with PRPP. The prepara-
tion of hemolysate and cultured ﬁbroblasts from skin
biopsies, as well as the details of the PRS-I enzymatic
activity assay, have been previously described.12–14
Statistically signiﬁcant reduction in PRS-I activity in
erythrocytes was observed (p < 0.05, calculated by CHISS
t test) when PRS-I activity in affected males was compared
to that in unaffectedmales and unrelated healthy controls.
In the two female carriers that we studied, no signiﬁcant
differences in PRS-I activity were noted in the same10
Figure 3. Structure of PRS-I in Complex with AMP
The substrate-binding pocket of PRS-I consists of a metal ion-
binding site (gray sphere), an ATP-binding site (represented by
AMP moiety of ATP as sticks), and an R5P-binding site (a SO4
2
ion occupies the position of the 50 phosphate of R5P). In this
ﬁgure, two different asymmetric subunits of PRS-I (aquamarine
and pale yellow) form a part of the hexamer interface, and all of
the structural elements in the pale yellow subunit are tagged
with an apostrophe.
(A) Location of Asp650 (magenta sticks) and Lys340 (green sticks
between the b20 strand and loop30).
(B) Location of Ala87 (green sticks in the purple b5 strand) and the
ATP-binding loop (marine loop7).
(C) Location of Ile290 (green sticks in the b14 strand) and of
loop22 (deep blue).
(D) Location of Gly306 (green sticks in the b14 strand) and the
allosteric site of PRS-I (an SO4
2 ion occupies the position of the
b-phosphate of ADP).







IV-1 M yes 4.22 (5 1.37) 38.5
IV-9 M yes 6.17 (5 0.31) 56.3
IV-34 M yes 6.80 (5 0.21) 62.1
IV-36 M yes 7.55 (5 0.10) 68.9
Female Carriers
III-27 F yes 11.29 (5 0.21) 103.1
III-29 F yes 9.73 (5 0.10) 88.9
Unaffected Males
IV-5 M no 9.89 (5 1.78) 90.3
IV-7 M no 10.27 (5 0.04) 93.8
Unrelated Controls
C-1 F no 10.87 (5 1.26) 99.3
C-2 M no 12.77 (5 1.16) 116.6
a The standard deviations is calculated from three experiments.
b Individual PRS-I activity / mean of the PRS-I activity of unaffected males and
controls.







IV-9 M yes 74.24 (5 1.81) 57.5
IV-36 M yes 68.07 (5 1.04) 52.7
Carriers
III-27 F yes 107.85 (5 11.36) 83.5
III-29 F yes 84.03 (5 4.56) 65.1
Unaffected Male
IV-7 M no 129.16 (5 1.19) 100
a The standard deviations is calculated from three experiments.
b Individual PRS-I activity / PRS-I activity of the unaffected male.comparisons (Table 2). In cultured skin ﬁbroblasts from
affected males IV-9 and IV-36, PRS-I activity was 74.24
and 68.07 nmol/mg/hr, respectively, which was lower
than the activity observed in unaffected male,IV-7
(129.16 nmol/mg/hr) (Table 3).
By in situ hybridization in the murine cochlea (as
described previously15), at embryonic day 18.5 (E18.5)
Prps1 expression was observed in hair cells, Claudius cells,
and the greater epithelial ridge (GER). Prps1 was also ex-
pressed in utricular and crista hair cells (data not shown).
By postnatal day 6 (P6), expression of Prps1 could beThe Adetected in the spiral ganglion cells in addition to hair cells
and Claudius cells, although expression in the GER was
reduced (Figure 4).
To date, seven missense mutations (D51H, L128I,
N113S, D182H, A189V, H192L, and H192Q) have been
identiﬁed in PRPS1 as causing PRS-I superactivity, which
results in PRPS1-related gout (MIM 311850).16,17 The
disorder is characterized by purine nucleotide and uric
acid overproduction and, occasionally, neurological prob-
lems.18 PRS-I superactivity has also been reported to cause
sensorineural hearing loss and developmental delay.19
Interestingly, recent studies have provided evidence that
missense mutations in PRPS1 can lead to decreased PRS-I
enzymatic activity in several syndromes. Two missensemerican Journal of Human Genetics 86, 65–71, January 8, 2010 69
Figure 4. Prps1 Expression in the Mouse Inner Ear
(A) With an antisense probe, Prps1 was observed at E18.5 as
robustly expressed in the cochlear hair cells (HC), the Claudius
cells (CC), and the greater epithelial ridge (GER), but not in other
cochlear supporting cells.
(B) A sense control probe did not produce any signals.
(C) At postnatal day 6, HC and CC expression of Prps1 was main-
tained, whereas expression in the GER was reduced. Prps1was also
expressed in the spiral ganglions (SG) at this stage.
(D) A sense control probe did not produce any signal. Magniﬁca-
tion 203.mutations (Q133P and L152P) in PRPS1 have been
described in Arts syndrome (MIM 301835), characterized
by mental retardation, early-onset hypotonia, ataxia, de-
layed motor development, hearing impairment, and optic
atrophy.14 E43D missense mutation was identiﬁed in a
syndromic form of inherited peripheral neuropathy
known as Rosenberg-Chutorian syndrome (RCS), and
M115T mutation was identiﬁed in an X-linked form of
Charcot-Marie-Tooth inherited neuropathy (CMTX5
[MIM 311070]).13 The CMTX5 syndrome is associated
with a symptom triad of sensorineural hearing loss, visual
impairment, and peripheral neuropathy, identical to that
reported in RCS. It is of note that CMTX5 and RCS are
allelic disorders sharing a common disease gene.
Our study extends the spectrum of PRPS1-related
disorders to include NSHL, seen in DFN2. Four missense
mutations (D65N, A87T, I290T, and G306R) have been
identiﬁed in four DFN2 families as resulting in a loss of
PRS-I activity, as was shown in silico by structural analysis
and was shown in vitro by enzymatic activity assays in
erythrocytes and cultured ﬁbroblasts from patients. None
of the mutations that we report are predicted to result
in a major structural change in the PRS-I protein, which
may explain why the disease phenotype is limited to
NSHL. Molecular modeling showed that the D65N
(DFN2), M115T (CMTX5), and Q133P (Arts syndrome)
mutations probably affect the ATP-binding pocket. The70 The American Journal of Human Genetics 86, 65–71, January 8, 20analysis predicted that the D65N mutation has a much
less severe effect on the binding of ATP, as compared
with the Q133P14 mutation, which has more severe conse-
quence than the M115T mutation.13
Further evidence comes from the comparison of the
severity of reduction of the PRS-I activity observed in
patients with DFN2, CMTX5, and Arts syndrome, with
a diverse spectrum of phenotypes in affected males. In
the family with Arts syndrome, there was no detectable
PRS-I activity in erythrocytes from the affected males.
The PRS-I activity of three patients was reduced 13-fold
in comparison to that in ﬁbroblasts from controls. The
phenotype of Arts syndrome exhibits mental retardation,
early-onset hypotonia, ataxia, delayed motor develop-
ment, hearing impairment, and optic atrophy. In the
CMTX5 family, the PRS-I activity in ﬁbroblasts from
affected males decreased by 62% (38% activity remained)
in comparison to that of an unaffected male and unrelated
healthy controls. The phenotype of CMTX5 syndrome is
reduced to hearing loss, visual impairment, and peripheral
neuropathy. Similar to that in the DFN2 family, the PRS-I
activity in erythrocytes and cultured ﬁbroblasts from
affected males has decreased by 44%–45% (55%–56%
activity remained) in comparison to that of normal male
family members and unrelated control subjects. The
phenotype of DFN2 is limited to NSHL.
By immunohistochemistry staining, we have shown that
Prps1was expressed inbothvestibular andcochleahair cells
in early developing and postnatal mice and could also be
detected in the spiral ganglion cells in mice at P6. The
Prps1 distribution pattern suggests a role in inner ear devel-
opment and maintenance. Basic physiological knowledge
suggests that DPOAEs can be frequency-speciﬁc tests of
cochlear status whenever pathology involves outer hair
cells. In family GZ-Z052, there was absence of detectable
DPOAEs in affected males and female carriers that were
tested, which indicate that hair cells are probably the
main site of pathology responsible for the hearing loss in
DFN2. There were no symptoms of auditory neuropathy
involving either the spiral ganglion cells or their axons,
nor was there any visual impairment from optic neurop-
athy. Thus, it is possible that the deafness observed in
DFN2 patients may be the consequence of defects of hair
cell origin.However, additional experiments are stillneeded
for elucidation of the exact pathological mechanisms that
lead to hearing loss in families with DFN2 mutations.
In summary, we have identiﬁed PRPS1 as the second
gene to be implicated in X-linked NSHL, by (1) identifying
missense mutations in PRPS1 in four DFN2 families, (2)
showing that these changes are within functional domains
of the PRS-I protein and thereby alter protein function
(shown for the D65N mutation), and (3) showing that
the changes are uniformly conserved from zebraﬁsh to
human. The audio proﬁle and clinical presentation of
persons with DFN2 is easily distinguished from that of
persons with DFN3 (POU3F4), which will facilitate the
genetic testing of these two types of X-linked NSHL.10
Supplemental Data
Supplemental Data include two tables and can be found with this
article online at http://www.ajhg.org/.
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